Journal of Pediatric and Adolescent Gynecology
Volume 21, Issue 3 , Pages 119-128 , June 2008

Polycystic Ovary Syndrome in Adolescents

  • R.F. O'Brien, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Rebecca F. O'Brien, MD, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115
    • ,
  • S.J. Emans, MD

References 

  1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223
  2. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab. 2002;16:263
  3. Ibanez L, Ferrer A, Ong K, et al. Insulin sensitization early after menarche prevents progression from precocious puberty to polycystic ovary syndrome. J Pediatr. 2004;144:23
  4. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492
  5. Trent ME, Rich M, Austin SB, et al. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2002;156:556
  6. Azziz R. Controversy in clinical endocrinology. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91:781
  7. Franks S. Controversy in clinical endocrinology. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91:786
  8. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181
  9. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens JR,  Haseltine FP,  Merriam GR editor. Polycystic Ovary Syndrome. Cambridge: Blackwell Scientific Publications; 1992;p. 377–384
  10. Balen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505
  11. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19
  12. Buggs C, Rosenfield R. Polycystic ovary syndrome in adolescence. Endocrinol Metabol Clin N Am. 2005;34:677
  13. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J. 1986;293:355
  14. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853
  15. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med. 2001;111:602
  16. Carmina E, Chu MC, Longo RA, et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545
  17. Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metabol. 1990;71:970
  18. Mortenson M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-sized ovaries in healthy adolescents. J Clin Endocrinol Metab. 2006;91:3786
  19. Rosenfield RL, Ghai K, Ehrmann DA, et al. Diagnosis of polycystic ovary syndrome in adolescence. Comparison of adult and adolescent hyperandrogenism. J Clin Endocrinol Metab. 2000;13(Suppl 5):1285
  20. Azziz R, Carmina E, Dewailly D, et al. Position Statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endo Metab. 2006;91:4237
  21. Emans SJ. Androgen abnormalities in the adolescent girl. In:  Emans SJ,  Laufer MR,  Goldstein DP editor. Pediatric and Adolescent Gynecology. 5th ed.. Philadelphi, Lippincott Williams & Wilkins; 2005;p. 287–333
  22. Hassan A, Gordon CM. Polycystic ovary syndrome update in adolescence. Curr Opin Pediatrics. 2007;19(4):389
  23. Gordon CM. Menstrual disorders in adolescents: Excess androgens and the polycystic ovary syndrome. Pediatr Clin North Am. 1999;46:519
  24. Wickenheisser JK, Quinn PG, Nelson VL, et al. Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab. 2000;85:2304
  25. Nelson CL, K-n Qin, Rosenfield RL, et al. The biochemical basis for increased testosterone secretion in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:5925
  26. Wickenheisser JK, Nelson-Degrave VL. McAllister JM: Dysregulation of cytochrome P450 17 [alpha]-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2005;90(3):1720
  27. Rosenfield RL. Ovarian an adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin. 1999;28:265
  28. Maciel GA. Stockpiling of transitional and primary follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2004;89:5321
  29. Coffler MS, Patel K, Dahan MH, et al. Evidence for abnormal granulose cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2003;88:1742
  30. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin. 1999;28:341
  31. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774
  32. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165
  33. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol. 2002;147:717
  34. Legro RS, Driscoll D, Strauss JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci. 1998;95:14956
  35. Legro RS, Kunselman AR, Demers L, et al. Male reproductive phenotype in PCOS families. J Clin Endocrinol Metab. 2002;87:2134
  36. Leibel NI, Baumann EA, Kocherginsky M. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab. 2006;91:1275
  37. Xita N, Tsatsoulis A. Review: Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical and genetic association studies. J Clin Endocrinol Metab. 2006;91:1660
  38. Ibanez L, Potau N, Virdis R, et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metabol. 1993;76:1599
  39. Ibanez L, Potau N, Zampolli M, et al. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab. 1997;82:2283
  40. Ibanez L, Dimartino-Nardi J, Potau N, et al. Premature adrenarche—normal variant or forerunner of adult disease?. Endocr Rev. 2000;21:671
  41. Warren-Ulnanch J, Aslanian S. Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metabol. 2006;20:311
  42. Androgen Excess Society: Tools to evaluate ovulation and hirsutism in women with potential androgen excess. Modifed Ferriman and Galwey scoring system. Available: http://www.ae-society.org/researchers2.html. Accessed May 7, 2007.
  43. Hillard PJA. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. Endocrinol Metab Clin N Am. 2005;34:707
  44. Dunaif A, Mandeli J, Fluhr H, et al. The impact of obesity and chronic hyperinsulinemia on gondatropin release and gonadal steroid secretion in polycystic ovary syndrome. J Clin Endocrin Metabol. 1988;66:131
  45. Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48:167
  46. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165
  47. Palmert M, Gordon CM, Kartashov AL, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2002;87:1017
  48. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;436:393
  49. Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Prac Res Clin Endocrinol Metab. 2006;20:293
  50. Ibanez L, de Zegher F. Flutamide-metformin plus oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod. 2006;19:1725
  51. Farquhar C, Lee O, Toosmath R, et al. Sprinolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2003;(4):CD000194
  52. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003;(4):CD001125
  53. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951
  54. Costello M, Shrestha B, Eden J, et al. Insulin-sensitizing drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD005552
  55. La Marca A, Artensio AC, Stabile G, et al. Metformin treatment of PCOS during adolescence and the reproductive period. Eur J Obstet Gynecol Reprod Biol. 2005;121:3
  56. Arslanian SA, Lewy V, Danadian K, et al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endo Metabol. 2002;87:1555
  57. Glueck CJ, Wang P, Fontaine R, et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health. 2001;29:160
  58. Ibanez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metabol. 2001;86:3595
  59. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type two diabetes. Pediatrics. 2001;107:E55
  60. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457
  61. Bridger T, MacDonald S, Baltzer F, et al. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006;160:241
  62. DeLeo V, Musacchio MC, Morgante G, et al. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod. 2006;121:2252
  63. Bruni V, Dei M, Pontello V, et al. The management of polycystic ovary syndrome. Ann N Y Acad Sci. 2003;997:307
  64. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update. 2006;12:243

PII: S1083-3188(07)00256-2

doi: 10.1016/j.jpag.2007.07.007

Journal of Pediatric and Adolescent Gynecology
Volume 21, Issue 3 , Pages 119-128 , June 2008

Article Tools

* Image Usage & Resolution